Treadwell Therapeutics, a NYC-based clinical-stage oncology company exploiting cancer cells’ vulnerabilities to develop small molecules to address unmet needs in patients with cancer, raised an initial $27m in seed financing.
TIO Bioventures, an emerging life science venture creation fund with a mission to build companies with innovative anti-cancer therapies, has launched the new company.
Treadwell Therapeutics exploits cancer cells’ vulnerabilities to develop first-in-class and best-in-class small molecules to address unmet needs in patients with cancer.
Based on research at the Campbell Family Institute for Breast Cancer Research (CFIBCR) within the University Health Network (UHN), Canada’s largest research hospital, the company’s internally developed pipeline includes a first-in-class PLK4 kinase inhibitor, CFI-400945 and a potentially best-in-class TTK inhibitor, CFI-402257 ready for Phase 2, and CFI-402411, an oral immunomodulatory kinase inhibitor with activity toward HPK1, which will enter the clinic in early 2020.
The team includes:
- Shane Burgess, OD, MBA, Co-Chief Executive Officer
- Michael W. Tusche, PhD, MBA, Co-Chief Executive Officer
- Jeff Rona, Chief Financial Officer
- Mark R. Bray, PhD, Co-Founder and Chief Scientific Officer
- Tak Wah Mak, PhD, Co-Founder
FinSMEs
13/01/2020